Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases. As a leading orphan endocrine disease company, we create distinct and transformative treatments for a wide range of endocrine diseases where there is a significant unmet medical need. We are currently advancing a pipeline that includes the following potentially first-in-class product candidates:

• Livoletide (AZP-531) for the treatment of Prader-Willi syndrome
• Nevanimibe (ATR-101) for the treatment of classic congenital adrenal hyperplasia
• MLE-301 for the treatment of vasomotor symptoms (VMS) associated with menopause